B+
Bull case
25%
Probability
Target price
$450.00
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
KRYS
Krystal BiotechBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Durable VYJUVEK growth, high gross margin, international expansion, substantial cash, and several 2026 registrational or interim readouts could support a transition toward a multi-product genetic-medicines platform. [#8-K-2026-08-03](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000058/a2q26-ex991xpressrelease.htm)
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +10.7.
What can break
Consensus surprise data, post-print estimate revisions, and analyst target changes are unavailable, limiting confidence in the earnings reaction assessment.
Momentum
55
Value
60
Sentiment
70
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $375.00 · Bull $450.00 · Bear $260.00Analysis 2026-08-06; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-06 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $385.00
Why
Momentum55 · Δ7d +26.0
Value60 · Δ7d -0.0
Sentiment70 · Δ7d +10.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +10.7.
Contradictions & invalidation
- • Consensus surprise data, post-print estimate revisions, and analyst target changes are unavailable, limiting confidence in the earnings reaction assessment.
- • European pricing and reimbursement discussions remain ongoing, including potentially extended negotiations in France, which could delay or alter international uptake. [#8-K-2026-08-03](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000058/a2q26-ex991xpressrelease.htm)
- • The commercial trajectory must absorb European pricing and reimbursement work while the valuation increasingly depends on clinical execution.
Catalyst clock
2026-08-14
Post-earnings estimate and reaction digestion
Lead driver: Sentiment · See AI snapshot
Momentum
55
9% active weight
Current posture
7d trendImproving
Δ7d
+26.0
Δ21d
+10.3
Value
60
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.4
Sentiment
70
62% active weight
Current posture
7d trendImproving
Δ7d
+10.7
Δ21d
-5.4
Why this grade
Composite grade B. Momentum 54.7 / Value 60.3 / Sentiment 69.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-06. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$375.00
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$260.00
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$9.94B
Beta
0.49
Shares Out
29.6M
P/E (TTM)
36.7
P/S (TTM)
19.02
P/FCF (TTM)
42.85
Rev YoY
+24.1%
EPS YoY
+38.6%
Gross Margin
+93.3%
Op Margin
+44.9%
Net Debt
-$818.45M
Current Ratio
8.32
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data